Evidence map›Paper›PMID 39535688›Full record

ReviewCurrent treatment options in oncology2024

Contemporary Review of Adenocarcinoma of the Cervix.

N Desravines, C Tran, S Wethington, M Y Williams-Brown

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

N DesravinesDivision of Gynecologic Oncology, Department of Women's Health, University of Texas at Austin Dell Medical School, Austin, TX, USA. nerlyne.desravines@austin.utexas.edu.
C TranDepartment of Women's Health, University of Texas at Austin Dell Medical School, Austin, TX, USA.
S WethingtonDivision of Gynecologic Oncology, Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, MD, USA.
M Y Williams-BrownDivision of Gynecologic Oncology, Department of Women's Health, University of Texas at Austin Dell Medical School, Austin, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

opinion statementAmong cervical cancers, adenocarcinoma is less common than squamous cell carcinoma of the cervix; however, the incidence of these cancers is rising. The incidence has changed largely due to a shift in risk factors as well as the evolution of the diagnosis and classification of adenocarcinoma. Adenocarcinoma of the cervix is composed of a diverse group of neoplasms that can be classified by various factors. In this review article, preinvasive disease, updated classifications of adenocarcinoma, and treatment options for cervical adenocarcinoma are discussed with a focus on current and future therapies. Advances in antibody-drug conjugates (ADC) and immunotherapy have increased the treatment options available for usual-type adenocarcinoma but there is still a lack of variety of treatment options for the remaining 25% of non-usual-type adenocarcinomas.

Indexed as

AdenocarcinomaUterine Cervical NeoplasmsCombined Modality TherapyDisease ManagementFemaleHumansImmunoconjugatesImmunotherapyNeoplasm StagingTreatment OutcomeImmunoconjugatesAdenocarcinoma of cervixAdenocarcinoma of uteri cervixCarcinoma of cervixEndocervical adenocarcinomaMalignant cervical neoplasmMalignant neoplasm of uteri cervix

Identifiers

PMID39535688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.